98%
921
2 minutes
20
Cholestasis is a major hepatic disease in infants, with increasing morbidity in recent years. Accumulating evidence has revealed that the gut microbiota (GM) is associated with liver diseases, such as non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, GM alterations in cholestatic infants and the correlation between the GM and hepatic functions remain uninvestigated. In this study, 43 cholestatic infants (IC group) and 37 healthy infants (H group) were enrolled to detect GM discrepancies using 16S rDNA analysis. The diversity in the bacterial community was significantly lower in the IC group than that in the H group ( = 0.013). After determining the top 10 abundant genera of microbes in the IC and H groups, we found that 13 of them were differentially enriched, including , and . As compared with the H group, the IC group had a more complex GM co-occurrence network featured by three core nodes: , and . In addition, the positive correlation between and ( = 0.689, = 0.000, FDR = 0.009) was not observed in the IC patients. Using the GM composition, the cholestatic patients can be distinguished from healthy infants with high accuracy [areas under receiver operating curve (AUC) > 0.97], wherein , and are identified as valuable biomarkers. Using KEGG annotation, we identified 32 functional categories with significant difference in enrichment of the GM of IC patients, including IC-enriched functional categories that were related to lipid metabolism, biodegradation and metabolism of xenobiotics, and various diseases. In contrast, the number of functions associated with amino acid metabolism, nucleotide metabolism, and vitamins metabolism was reduced in the IC patients. We also identified significant correlation between GM composition and indicators of hepatic function. positively correlated with total bilirubin ( = 0.455, = 0.002) and direct bilirubin ( = 0.441, = 0.003), whereas γ-glutamyl transpeptidase was positively associated with ( = 0.466, = 0.002) and negatively related to ( = -0.450, = 0.003). This study describes the GM characteristics in the cholestatic infants, illustrates the association between the GM components and the hepatic function, and provides a solid theoretical basis for GM intervention for the treatment of infantile cholestasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243132 | PMC |
http://dx.doi.org/10.3389/fmicb.2018.02682 | DOI Listing |
Acta Med Philipp
July 2025
Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila.
Objective: Phenobarbital is an inductor of microsomal hepatic enzyme and used as choleretic for cholestatic liver disease to enhance bile flow. It is also used as a premedication for hepatobiliary scintigraphy (HIDA) scan to improve diagnostic accuracy for an obstructive liver disease. We reviewed the available literature on the use of Phenobarbital for treatment of cholestasis and its utility as a premedication for HIDA scan.
View Article and Find Full Text PDFInt J Surg Case Rep
August 2025
Department of Pediatric Surgery, Ehime Prefectural Central Hospital, Ehime, Japan. Electronic address:
Introduction: Biliary atresia (BA) is a progressive cholestatic disease in neonates and infants, and early diagnosis and treatment significantly impact prognosis. Definitive diagnosis is based on cholangiogram findings, classifying BA into three main types. Among its variants, type I-b1-β-where the common bile duct is blocked, the distal duct is fibrous, and the tiny intrahepatic ducts are underdeveloped-is particularly rare.
View Article and Find Full Text PDFMol Syndromol
August 2025
Division of Pediatric Genetics, Department of Pediatrics, Mersin City Training and Research Hospital, Mersin, Turkey.
Introduction: Cholestasis in childhood is a rare clinical condition, yet a definitive diagnosis is crucial for initiating treatment of these curable diseases and preventing related morbidity and mortality. The most common cause of infant cholestasis is biliary atresia (25-40%), followed by monogenic cholestatic diseases (25%), metabolic diseases (20%), and cryptogenic cholestasis. This study focuses on assessing the clinical utility of next-generation sequencing (NGS) panels, including clinical exome sequencing and whole exome sequencing, in diagnosing cholestatic diseases when the etiology cannot be elucidated through conventional methods.
View Article and Find Full Text PDFWorld J Hepatol
July 2025
Division of Pediatric Gastroenterology, Sheikh Khalifa Medical City, Abu Dhabi 51900, United Arab Emirates.
Progressive familial intrahepatic cholestasis (PFIC) is a group of rare, inherited cholestatic liver disorders presenting in infants and children and are associated with impaired bile flow (, cholestasis), pruritus and progressive liver disease. Historically there has been no effective or approved pharmacologic treatments for these disorders and standard medical treatment has only been supportive. The impaired bile flow within the liver, leads to accumulation in the liver and inflammation.
View Article and Find Full Text PDFJ Pediatr Gastroenterol Nutr
July 2025
Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan.
Objectives: Cholestasis in infancy poses a complex clinical conundrum for pediatric hepatologists, warranting timely diagnosis, especially for genetic diseases. This study aims to create machine learning (ML)-based prediction models, referred to as Jaundice Diagnosis Easy for Baby (JADE-B), to identify the subjects prone to genetic causes of cholestasis.
Methods: We retrieved patient data from the Integrated Medical Database at a university-affiliated tertiary medical center from 2006 to 2018.